Rallybio Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLYB research report →
Price Chart
About the company
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- CEO
- Stephen Uden
- IPO
- 2021
- Employees
- 7
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on RLYB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $90.64M
- P/E
- 2.15
- Fwd P/E
- 4.36
- PEG
- 0.00
- P/S
- 140.31
- P/B
- 1.03
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
- Gross Margin
- -1107.59%
- Op Margin
- -3672.29%
- Net Margin
- 7051.24%
- ROE
- 68.56%
- ROIC
- -24.40%
Latest fiscal year · YoY change
- Revenue
- $858.00K+34.9%
- Gross Profit
- $766.00K+102.0%
- Op Income
- $-28,064,000
- Net Income
- $-8,978,000+84.5%
- EPS
- $-1.59+85.1%
- OCF Growth
- +39.5%
- FCF Growth
- +39.5%
- 52W High
- $17.57
- 52W Low
- $3.67
- 50D MA
- $16.71
- 200D MA
- $11.91
- Beta
- -0.85
- RSI (14)
- 54
- Avg Volume
- 22.66K
No earnings-call transcripts are available for RLYB yet.
- Free Float
- 54.4%
- Shares Outstanding
- 5.31M
- Float Shares
- 2.89M
of shares held by institutions
38 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3.30M | 0 |
| Vanguard Group Inc | 1.02M | ▲ 16.62K |
| Adar1 Capital Management, LLC | 926.35K | ▲ 905.82K |
| Fmr LLC | 794.72K | ▲ 1.27K |
| Viking Global Investors LP | 524.35K | 0 |
| Tpg Gp A, LLC | 378.55K | 0 |
| Pivotal Bioventure Partners Investment Advisor LLC | 300.58K | 0 |
| Renaissance Technologies LLC | 199.91K | ▲ 43.38K |
| Nantahala Capital Management, LLC | 188.42K | ▼ 112.21K |
| Vanguard Capital Management LLC | 172.50K | ▲ 60.46K |
| Almitas Capital LLC | 120.68K | ▼ 70.52K |
| Rangeley Capital, LLC | 104.85K | ▲ 74.72K |
Held by 34 ETFs
Biggest fund positions in RLYB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 26 | Lieber Jonathan I | other | 5,000 |
| Sep 29, 26 | Lieber Jonathan I | other | 5,000 |
| Sep 24, 26 | Liu Hui | other | 8,482 |
| Sep 24, 26 | Liu Hui | other | 3,562 |
| Sep 24, 26 | Liu Hui | other | 3,562 |
| Sep 24, 26 | Liu Hui | other | 8,482 |
| Sep 16, 26 | Chung Wendy | other | 3,562 |
| Sep 16, 26 | Chung Wendy | other | 3,562 |
| Jul 6, 26 | Boudreau Helen M | other | 3,562 |
| Jul 6, 26 | Boudreau Helen M | other | 3,562 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RLYB coverage
Recent articles, reports, and earnings notes.
No research on RLYB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLYB report →Rallybio (NASDAQ:RLYB) Stock Price Up 1.9% – Should You Buy?
defenseworld.net · Oct 4
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
gurufocus.com · Jul 21
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jul 21
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
gurufocus.com · Jun 9
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jun 9
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
gurufocus.com · Jun 2
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
businesswire.com · Jun 2
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
prnewswire.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.